Management of osteoporosis: fracture prevention

March 7, 2019

Contributed by

Erika Dempsey, MD FRCPC
(Read bio)

Case

Ms Y is a 72 year old woman with a history of hypertension, osteoarthritis and well controlled Gastroesophageal reflux disease (GERD). She presents for a periodic health maintenance visit and seems generally well. Her current medications are Ramipril, hydrochlorothiazide and pantoprazole. Your EMR reminds you that she has not been screened for osteoporosis.

Objectives

  • Be comfortable using established tools to estimate fracture risk and utilize that risk, not bone mineral density alone, to counsel patients regarding medications for osteoporosis.
  • Be aware of the large gap in care for patients with osteoporosis.
  • Understand benefits and risks of first line medications for osteoporosis.

This article focuses on post-menopausal osteoporosis and follows the Toward Optimized Practice (TOP) guidelines1 on the topic.

The disease

Osteoporosis is a disease of compromised bone strength which can lead to increased risk of fracture. Bone strength reflects a combination of bone density and bone quality.2 Osteoporosis leads to an increased incidence of fractures resulting from low impact trauma (or no trauma in the case of numerous vertebral fractures). 80% of all fractures in patients over the age of 50 are thought to be related to osteoporosis.3

Screening

To identify those at high risk, individuals over the age of 50 should be assessed periodically with focused history and physical exam for risk factors for osteoporosis and fracture.4 This includes a review of previous fragility fracture (a fracture resulting from a fall from standing height or less), parental hip fracture, current smoking, consumption of >3 units alcohol/day, history of use of corticosteroids and past medical history. History of falls within the past year and problems with gait and balance are also important to review. Low weight (<60kg in men, <50kg in women) or significant (>10%) weight loss, and loss of height (potentially indicative of vertebral compression factures) increase the risk of fracture.5

Patients with endocrine disease (hyperparathyroidism, hyperthyroidism, hypogonadism, diabetes), malabsorption (celiac disease, inflammatory bowel disease, cystic fibrosis), and rheumatologic illness are at higher risk of osteoporosis. Glucocorticoids, anticonvulsants, proton-pump inhibitors and numerous other medications can also contribute to fracture risk through a variety of mechanisms.6

Estimating risk

Bone mineral density (BMD) as measured by DEXA (dual energy x-ray absorptiometry) is commonly used to diagnose low bone density. It also indicates a measurement for individuals > 65 years or those with increased risk of osteoporosis. BMD is generally reported as an exact density as well as a T score (the number of standard deviations away from the density of a healthy 20 year old female7). Bone density, however, may misrepresent a person’s true probability of fracture.

Bone quality, the other major component of bone strength, cannot yet be clinically measured.8

A number of tools exist to help clinicians estimate fracture risk. CAROC9 is one recommended by Osteoporosis Canada. It uses age, gender, BMD at femoral neck and presence/absence of previous fragility fracture to estimate fracture risk. The Fracture Risk Assessment Tool (FRAX) was developed and validated by the WHO and can be done with or without a BMD measurement. Patients with a 20% probability of fracture within the next 10 years are considered to be “high risk”. Neither tool takes into account a patient’s risk of falling.

A previous fragility fracture is a strong indicator of poor bone quality and future fracture risk. It is generally agreed that patients experiencing a vertebral or hip fracture have established osteoporosis.10 In the absence of BMD, a wrist fracture portends a 14.2% 10-year probability of second fracture. A vertebral fracture has a 25.7% probability, a hip fracture has 24.9% and humerus fracture 23.7%.11 Perhaps most importantly, up to half of patients with hip fractures have previously sustained fractures, indicating a missed opportunity to initiate secondary prevention.12

Care gap

Osteoporosis is exceedingly costly, both for the patient and the health care system. Osteoporosis Canada estimates, based on CIHI data, that acute care for patients with hip fractures alone will cost Alberta over $62 million in 2020.13 This does not include increased costs of care post discharge.14 Roughly a quarter of patients with hip fractures will require institutional care post discharge . Mortality is increased post vertebral and hip fracture approximately threefold.15 One year post-op mortality for hip fracture patients is 25-30%.16

Despite the fact that we have validated tools for calculating fracture risk and decades of experience using medications to lower that risk, many patients are not on treatment.17 Patients who have experienced a fragility fracture are often not screened for osteoporosis or offered appropriate therapy and rates are worsening over time.18

In an effort to increase the number of patients appropriately treated for osteoporosis after an initial fragility fracture, the Alberta Health Services Bone and Joint Health Strategic Clinical Network has implemented a variety of Fracture Liaison Services (FLS).19 This includes Catch A Break20 which alerts patients with a wrist, humerus, pelvis or lower leg fracture to an increased risk of future fracture and encourages them to contact their physician for further evaluation. FLS are now embedded in a number of hospitals across most zones to evaluate, initiate therapy and follow patients for one year after hip fracture.

Medications

Patients with moderate probability (10-19.9%) of fracture should consider pharmacologic treatment and patients with high probability (>20%) should strongly consider therapy in the absence of contraindications.21 All treatment should be accompanied by Vitamin D supplementation (800-2000 IU daily) and 1200 mg/day of (preferably dietary) calcium.

Oral and IV bisphosphonates and denosumab have all demonstrated efficacy at reducing vertebral, non-vertebral and hip fractures, and are recommended first line therapy.22 Teriparitide (an anabolic agent) is also first-line but is not reviewed here due to high cost. Recent meta-analysis suggests that denosumab improves bone density measurements but there is not enough data to claim that it is superior at preventing clinical fractures.23 Note that etidronate (Didrocal) is not effective at reducing non-vertebral fractures.24

Bisphosphonates work by inhibiting osteoclasts, decreasing their ability to resorb bone and helping to restore the disrupted balance between bone resorption and bone building that occurs post-menopause in women and with aging in some men. Once weekly oral bisphosphonates (alendronate and risedronate) are first line treatment for osteoporosis.25 They are generally well tolerated, although they do have specific instructions such as take on an empty stomach with a full glass of water and remain upright and fasting for 30-60 minutes afterwards. Zoledronic acid is a parenteral alternative, infused annually. Bisphosphonates are renally cleared and are contraindicated in CrCl <35 mL/min (30 mL/min in risedronate).

Denosumab is a human monoclonal antibody that binds to cytokine RANKL, inhibiting osteoclast maturity and function. By blocking osteoclast action, it is also an anti-resorptive agent. Denosumab is administered every six months via subcutaneous injection.

Adverse events

Common side effects to oral bisphosphonates include reflux, esophagitis and gastrointestinal ulcers. IV zoledronic acid can cause flu-like illness within one-to-three days of infusion. There is some suggestion of increased atrial fibrillation with IV bisphosphonates, but the data remains mixed at this point.26

Rare but serious side effects associated with antiresorptives (bisphosphonate related osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF)) have been well publicized and have likely led to a decreased uptake. The risk of these are low; NNH in the case of AFF is estimated as 200027 and for ONJ is between 10,000-100,000 (the NNH is smaller in doses of antiresorptives used for treatment of malignancy).28 Similar adverse events have been found for denosumab.29,30 It is key to understand that the number of osteoporotic fractures that are prevented by these treatments far exceeds the incidence of these adverse events.

Patients taking these medications should be counselled appropriately about how to monitor and prevent these side effects – i.e., maintaining good oral hygiene and anticipating invasive dental procedures prior to starting bisphosphonate therapy may help prevent bisphosphonate related ONJ.31 Patients should notify their health care provider if they develop new thigh or groin pain while on bisphosphonates (and providers should strongly consider bilateral full femoral x-rays +/- bone scan) to look for cortical thickening or incomplete fractures.

Because denosumab is not renally cleared it has been considered an attractive option for treating osteoporosis in patients with chronic kidney disease (CKD). Unfortunately, in patients with CrCl <30 mL/min, there is an increased risk of clinically significant hypocalcemia post injection.32 Overall, fracture risk in patients with CKD is complex, and likely best managed by nephrology.33

Duration of therapy

Because the risk of AFF may increase with longer duration of bisphosphonate use, and because bisphosphonates accumulate in bone, the American Society of Bone Mineral Research algorithm recommends that patients who are initially at high risk and remain at high risk receive an oral bisphosphonate for 10 years and six years of IV zolendronic acid. The risk/benefit ratio beyond these times is currently unknown. For lower risk patients, consider a drug holiday after five years of clinical stability (no fractures, stable BMD) or three years of zoledronic acid.34

There appears to be a short-term increase in the number of vertebral compression fractures after stopping denosumab, so the current pattern of practice is to continue it indefinitely or change to a bisphosphonate to avoid this.35 This becomes a challenge if denosumab is stopped due to worsening kidney function where bisphosphonates are contraindicated.

Back to the case

On further history you note that Ms Y had a wrist fracture at the age of 62. Her mother had a hip fracture which precipitated a move to long term care. She had one fall in the past year and is “not as quick as she used to be.” On exam she is 58kg and 162cm. She is not a smoker and does not drink regularly. She has no illnesses that predispose her to osteoporosis. Her estimated glomerular filtration rate is 52 mL/min. She has never had a BMD. You calculate her FRAX score in the absence of a BMD as a 34% chance of a major osteoporotic fracture and 18% chance of hip fracture within the next 10 years.

You counsel her regarding the risks and benefits of the medication and she agrees to take alendronate once weekly in addition to dietary calcium and vitamin D 1000-2000 U daily. In the event that her GERD significantly worsens with alendronate, you can trial risedronate once weekly. If both agents are intolerable, the Alberta Blue Cross Coverage for Seniors benefit has special authorization for annual IV zoledronic acid which can be administered at local infusion centres or in the person’s home, or semi-annual denosumab injections which can be provided by physicians, nurses and many pharmacists.

Together you agree to bring her in shortly to review balance and falls risk.

References

    1. Towards Optimized Practice. (2016). Diagnosis and management of osteoporosis. Retrieved from https://www.topalbertadoctors.org/download/1907/Osteoporosis%20CPG.pdf  
    2. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. American association of clinical endocrinologists and american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016--executive summary. Endocr Pract. 2016 Sep;22(9):1111-8. doi: 10.4158/EP161435.ESGL.
    3. https://osteoporosis.ca/about-the-disease/  
    4. Alexandra Papaioannou, Suzanne Morin, Angela M. Cheung, Stephanie Atkinson, Jacques P. Brown, Sidney Feldman, David A. Hanley, Anthony Hodsman, Sophie A. Jamal, Stephanie M. Kaiser, Brent Kvern, Kerry Siminoski, William D. Leslie and ; for the Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ November 23, 2010 182 (17) 1864-1873; DOI: https://doi.org/10.1503/cmaj.100771
    5. Alexandra Papaioannou, Suzanne Morin, Angela M. Cheung, Stephanie Atkinson, Jacques P. Brown, Sidney Feldman, David A. Hanley, Anthony Hodsman, Sophie A. Jamal, Stephanie M. Kaiser, Brent Kvern, Kerry Siminoski, William D. Leslie and ; for the Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ November 23, 2010 182 (17) 1864-1873; DOI: https://doi.org/10.1503/cmaj.100771
    6. Bowles, S.K., 2011. Drug-induced osteoporosis. PSAP VII, 203–224.
    7. El Maghraoui A, Roux C. DXA scanning in clinical practice. QJM. 2008;101(8):605. Epub 2008 Mar 10.
    8. Sözen, T., Özışık, L, Başaran, NC. An overview and management of osteoporosis. Eur J Rheumatol. 2017 Mar; 4(1): 46–56. doi: 10.5152/eurjrheum.2016.048
    9. https://www.osteoporosis.ca/multimedia/pdf/CAROC.pdf  
    10. Bauer, D. Osteoporosis Treatment After Hip Fracture: Bad News and Getting Worse. JAMA Netw Open. 2018;1(3):e180844. doi:10.1001/jamanetworkopen.2018.0844
    11. Hodsman, A. Leslie, W. Tsang, J., Gamble, G. 10-Year Probability of Recurrent Fractures Following Wrist and Other Osteoporotic Fractures in a Large Clinical CohortAn Analysis From the Manitoba Bone Density Program. Arch Intern Med. 2008;168(20):2261-2267. doi:10.1001/archinte.168.20.2261
    12. Port L, Center J, Briffa NK, Nguyen T, Cumming R, Eisman J (2003) Osteoporotic fracture: missed opportunity for intervention. Osteoporos Int 14:780–784
    13. Osteoporosis Canada’s Make the FIRST break the LAST with Fracture Liaison Services, October 2013 – available online at osteoporosis.ca/FLS.
    14. Papaioannou A, Wiktorowicz M, Adachi JD et al. Mortality, independence in living, and re‐fracture, one year following hip fracture in Canadians. J Soc Obstet Gynaecol Can 2000;22(8):591‐597.
    15. Ioannidis G, Papaioannou A, Hopman WM et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009;181(5):265‐271
    16. Panula, J., Pihlajamaki, H., Mattila, VM., Jaatinen, P. Vahlberg, T., Aarnio, P., Kivela, S. Mortality and cause of death in hip fracture patients aged 65 or older - a population-based study BMC Musculoskelet Disord. 2011; 12: 105. . doi: 10.1186/1471-2474-12-105
    17. Port L, Center J, Briffa NK, Nguyen T, Cumming R, Eisman J (2003) Osteoporotic fracture: missed opportunity for intervention. Osteoporos Int 14:780–784
    18. Desai, R., Mahesri, M., Abdia, Y., Barberio, J., Tong, A., Zhang, D., Mavros, P., Kim, S., Franklin, J. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures An Instrumental Variable Analysis JAMA Netw Open. 2018;1(3):e180826. doi:10.1001/jamanetworkopen.2018.0826
    19. de Bruin IJA, Wyers CE, van den Bergh JPW, Geusens PPMM. Fracture liaison services: do they reduce fracture rates? Ther Adv Musculoskelet Dis. 2017 Jul;9(7):157-164. doi: 10.1177/1759720X17706464.
    20. https://myhealth.alberta.ca/Alberta/Pages/Catch-a-break.aspx. Accessed Jan 10, 2019.
    21. Towards Optimized Practice. (2016). Diagnosis and management of osteoporosis. Retrieved from https://www.topalbertadoctors.org/download/1907/Osteoporosis%20CPG.pdf  
    22. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. American association of clinical endocrinologists and american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016--executive summary. Endocr Pract. 2016 Sep;22(9):1111-8. doi: 10.4158/EP161435.ESGL.
    23. Wu J1, Zhang Q1, Yan G1, Jin X2. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis. J Orthop Surg Res. 2018 Aug 2;13(1):194. doi: 10.1186/s13018-018-0865-3.
    24. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, Coyle D, Tugwell P. (2008) Etidronate for preventing fractures caused by osteoporosis in postmenopausal women. Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD003376.pub3
    25. Towards Optimized Practice. (2016). Diagnosis and management of osteoporosis. Retrieved from https://www.topalbertadoctors.org/download/1907/Osteoporosis%20CPG.pdf  
    26. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 2009;32(3):219.
    27. Khan, AA, Kaiser, S. Atypical Femoral Fractures. CMAJ April 10, 2017 189 (14) E542; DOI: https://doi.org/10.1503/cmaj.160450  
    28. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3.
    29. Drug Safety Update February 2013, vol 6, issue 7: A1. Accessed at: https://www.gov.uk/drug-safety-update/denosumab-60-mg-prolia on Jan 10, 2019.
    30. Boquete-Castro A1, Gómez-Moreno G2, Calvo-Guirado JL3, Aguilar-Salvatierra A4, Delgado-Ruiz RA5. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.Clin Oral Implants Res. 2016 Mar;27(3):367-75. doi: 10.1111/clr.12556. Epub 2015 Feb 2.
    31. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3.
    32. Nitta, K., Yajima, A., Tsuchiya, K. Management of osteoporosis in chronic kidney disease. Intern Med. 2017. Dec 15; 56(24):3271-3276. Doi:10.2169/internalmedicine.8618-16
    33. Towards Optimized Practice. (2016). Diagnosis and management of osteoporosis. Retrieved from https://www.topalbertadoctors.org/download/1907/Osteoporosis%20CPG.pdf  
    34. Adler et a; Managing Osteoporosis in Patients on Long‐Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. 2015
    35. Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Stopping Denosumab. Curr Osteoporos Rep. 2019 Jan 18. Doi: 10.1007/s11914-019-00502-4. [Epub ahead of print]

The AMA advances patient-centered, quality care by advocating for and supporting physician leadership and wellness.